Results 31 to 40 of about 507,938 (128)

Updated Efficacy Data –GARDASIL®

, 2020
2007 February 22, Eliav Barr, Program Head HPV Vaccines, Merck Research Laboratories presented an update of efficacy findings in the clinical program for Gardasil (quadrivalent HPV vaccine) during the ACIP ...
Barr, Eliav
core   +1 more source

HPV Vaccine Gardasil®-9 : What You Need to Know [PDF]

, 2015
This paper describes Gardasil®-9, its risks, and what to do if there is a serious ...
South Carolina Department of Health and Environmental Control
core   +1 more source

GARDASIL®9 (Human Papillomavirus 9-Valent Vaccine, Recombinant 9vHPV) in prevention of Cervical Cancer in Adolescent Females.

, 2021
Purpose: This study aims to prove the significance of early GARDASIL®9 vaccination in adolescent females before exposure to HPV and targeting all ethnic groups in HPV awareness.
Leriche, Rose-Marie P
core   +1 more source

A Critical Discourse Analysis of the Marketing of Merck & Co.\u27s Human Papillomavirus Vaccine Gardasil® [PDF]

, 2011
This is a critical discourse analysis research project that examines the print and television advertisements of Merck & Co.’s Human Papillomavirus (HPV) vaccine GARDASIL®.
Redmond, Malika A
core   +1 more source

Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine [PDF]

, 2019
Bivalent (Cervarix®) and quadrivalent (Gardasil®) Human Papillomavirus (HPV) vaccines demonstrate remarkable efficacy against the targeted genotypes, HPV16 and HPV18, but also a degree of cross-protection against non-vaccine incorporated genotypes, HPV31
Andrews, N, Turner, Paul, Panwar, K, Godi, A, Haque, M, Southern, J, Miller, E, Beddows, S, Cocuzza, CE   +8 more
core   +1 more source

Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine

Frontiers in Cellular and Infection Microbiology, 2019
Aim: This study aimed to follow the impact of human papillomavirus (HPV) catch-up and vaccination on the very high cervical HPV-prevalence in women at a youth clinic in central Stockholm during the period 2008–2018.Background: 2008–2010, cervical HPV ...
Andreas Ährlund-Richter, Liqin Cheng, Yue O. O. Hu, Yue O. O. Hu, Mikaela Svensson, Alexandra A. L. Pennhag, Alexandra A. L. Pennhag, Ramona G. Ursu, Ramona G. Ursu, Linnea Haeggblom, Nathalie Grün, Torbjörn Ramqvist, Lars Engstrand, Lars Engstrand, Tina Dalianis, Juan Du   +15 more
doaj   +1 more source

HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis

BMC Infectious Diseases, 2018
Background Recurrent respiratory papillomatosis (RRP) is a rare, benign disease of the aerodigestive tract, especially the larynx, caused by infection with the human papillomavirus (HPV) types 6 or 11.
Paul Stefan Mauz, Fabian Axel Schäfer, Thomas Iftner, Phillipp Gonser   +3 more
doaj   +1 more source

Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques

Papillomavirus Research, 2020
Human papillomavirus (HPV) causes not only most cervical cancers but also cancers of the vagina, vulva, penis, anus, rectum, and oropharynx. Every year, 200,000 women die of cervical cancer in the world, and China accounts for about 10%. HPV vaccines are
Yan Wang, Yuying Liu, Shutian Liang, Fei Yin, Haijiang Zhang, Yongjiang Liu   +5 more
doaj   +1 more source

Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. [PDF]

PLoS ONE, 2010
BACKGROUND: Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™)
Holly J Corbett, Germain J P Fernando, Xianfeng Chen, Ian H Frazer, Mark A F Kendall   +4 more
doaj   +1 more source

Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom

Journal of Health Economics and Outcomes Research, 2022
# Background The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. # Objective To estimate and compare the health and economic outcomes of 2 HPV vaccination
Kwame Owusu-Edusei, Cody Palmer, Olga Ovcinnikova, Giampiero Favato, Vincent Daniels   +4 more
doaj   +2 more sources